Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer

To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primar...

Full description

Saved in:
Bibliographic Details
Published in:Cancer investigation 2009-01, Vol.27 (5), p.549-560
Main Authors: Vanaja, Donkena Krishna, Ehrich, Mathias, Van den Boom, Dirk, Cheville, John C., Karnes, R. Jeffrey, Tindall, Donald J., Cantor, Charles R., Young, Charles Y.F.
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - genetics
CpG Islands
CpG site methylation
DNA Methylation
DNA, Neoplasm - genetics
Gene Expression Regulation, Neoplastic
Humans
Male
Mass spectrometry assay
Molecular markers
Neoplasm Recurrence, Local - diagnosis
Neoplasm Recurrence, Local - genetics
Polymerase Chain Reaction
Prostate cancer
Prostatic Hyperplasia - diagnosis
Prostatic Hyperplasia - genetics
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - genetics
Recurrence prediction
Risk Factors
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primary prostate tumors, and 32 benign prostate tissues using EpiTYPER technology. Specific CpG site hypermethylation of RARB2 and GSTP1 CpG sites were useful for diagnosis of prostate cancer. Furthermore, CpG site hypermethylation of genes FLNC, EFS, ECRG4, PITX2, PDLIM4, and KCNMA1 were associated with prediction of biochemical, local, and systemic recurrence of prostate cancer.
ISSN:0735-7907
1532-4192
DOI:10.1080/07357900802620794